Photo of Michelle Yeary

So learned some plaintiffs in In re: Hair Relaxer Marketing Sales Practices and Products Liability Litigation, MDL 3060, 2024 U.S. Dist. LEXIS 206474 (N.D. Ill. Nov. 13, 2024).  While not a drug or device case, the problem it exhibits is common to many mass torts.  Plaintiffs’ counsels’ solicitations produce a rush to file complaints

In re Deepwater Horizon Belo Cases, — F.4th –, 2024 WL 4522690 (11th Cir. Oct. 18, 2024), is not a drug or device case. It is the Eleventh Circuit’s review of the Northern District of Florida’s exclusion of the plaintiffs’ general causation experts in a toxic tort exposure case arising from the

Anyone who knows this blogger is well aware this is a topic near and dear to her heart.  For years, plaintiffs railed against defendants making “boilerplate” objections to discovery requests.  So much so that the issue was addressed by the 2015 Amendments to the Federal Rules of Civil Procedure.  While Rule 33 for interrogatories already

So learned plaintiff in United States ex rel. Plaintiff v. Novo Nordisk, Inc., 2024 U.S. Dist. LEXIS 174825 (W.D. Wash. Sept. 26, 2024), when the court granted defendant’s two motions to compel obviously relevant documents and information.

Plaintiff relator and intervening plaintiff, the State of Washington, assert False Claims Act (“FCA”) claims against the

Plaintiffs naming local sales representatives—or doctors, or pharmacies, or distributors, or retailers—as defendants to try to destroy diversity and avoid federal court is nothing new.  Unfortunately, defendants bear a “heavy burden” proving fraudulently joinder.  In fact, our last post on the topic was in February 2023, demonstrating that successes on this issue are few